Mark A. Velleca
CIK 1706847 · PRESIDENT & CEO · last filed 2026-01-23
Mark A. Velleca is a PRESIDENT & CEO who has filed 45 SEC Form 4 insider transactions across 2 companies since 2017. The most recent filing, for BDTX, was dated Jan 23, 2026. Across all open-market trades the lifetime net is −$8.9M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $212.7K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$212.7K
2
45
-$8.88M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| BDTX | PRESIDENT & CEO | 121,522 | $1.75 | $212.7K | $0 | 13 | 2026-01-23 |
| G1 Therapeutics, Inc. (GTHX) Delisted | Director | 173,286 | $7.15 | $1.24M | -$8.88M | 32 | 2023-08-10 |
Recent Filings
45 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-01-23 | BDTX | Grant (A) | — | $0 | EDGAR |
| 2025-01-31 | BDTX | Grant (A) | +75,000 | $0 | EDGAR |
| 2024-02-15 | BDTX | Grant (A) | — | $0 | EDGAR |
| 2023-09-18 | BDTX | Grant (A) | +5,208 | $18.7K | EDGAR |
| 2023-08-10 | G1 Therapeutics, Inc. (GTHX) Delisted | Mixed | — | -$96.8K | EDGAR |
| 2023-06-16 | BDTX | Grant (A) | +8,929 | $18.8K | EDGAR |
| 2023-05-17 | BDTX | Grant (A) | — | $0 | EDGAR |
| 2023-03-20 | BDTX | Grant (A) | +11,228 | $18.8K | EDGAR |
| 2022-12-19 | BDTX | Grant (A) | +8,424 | $12.6K | EDGAR |
| 2022-10-20 | G1 Therapeutics, Inc. (GTHX) Delisted | Mixed | — | -$169.6K | EDGAR |